JAGX
Jaguar Health·NASDAQ
--
--(--)
--
--(--)
0.82 / 10
Underperform
Financial analysis yields a poor rating (0.8/10). Key metrics reveal distress: ROA (%) is -53.43, Annualized net profit margin on total assets (%) is -106.85, and Net cash flow from operating activities / Operating revenue (%) is -327.30. Only Net profit / Total profit (%) at 100.0% offers a minor offset, but it is insufficient to counteract the severe profitability and cash-flow challenges. Overall, the company's financial health is fragile.
Analysis Checks(0/4)
ROA (%)
Value-53.43
Score0/3
Weight29.92%
1M Return-7.20%
Value-53.43
Score0/3
Weight29.92%
1M Return-7.20%
Annualized net profit margin on total assets (%)
Value-106.85
Score0/3
Weight29.92%
1M Return-7.20%
Value-106.85
Score0/3
Weight29.92%
1M Return-7.20%
Net cash flow from operating activities / Operating revenue (%)
Value-327.30
Score0/3
Weight26.77%
1M Return-6.20%
Value-327.30
Score0/3
Weight26.77%
1M Return-6.20%
Net profit / Total profit (%)
Value100.00
Score1/3
Weight13.39%
1M Return-2.49%
Value100.00
Score1/3
Weight13.39%
1M Return-2.49%
ROA (%)
Value-53.43
Score0/3
Weight29.92%
1M Return-7.20%
Value-53.43
Score0/3
Weight29.92%
1M Return-7.20%
Net cash flow from operating activities / Operating revenue (%)
Value-327.30
Score0/3
Weight26.77%
1M Return-6.20%
Value-327.30
Score0/3
Weight26.77%
1M Return-6.20%
Annualized net profit margin on total assets (%)
Value-106.85
Score0/3
Weight29.92%
1M Return-7.20%
Value-106.85
Score0/3
Weight29.92%
1M Return-7.20%
Net profit / Total profit (%)
Value100.00
Score1/3
Weight13.39%
1M Return-2.49%
Value100.00
Score1/3
Weight13.39%
1M Return-2.49%
Is JAGX undervalued or overvalued?
- JAGX scores 0.82/10 on fundamentals and holds a Premium valuation at present. Backed by its -455.44% ROE, -348.22% net margin, -0.07 P/E ratio, 0.64 P/B ratio, and -100.53% earnings growth, these metrics solidify its Underperform investment rating.
